EBS
Emergent BioSolutions Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$472M
5Y Perf.-89.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
EBS vs PRGO
Revenue, margins, valuation, and 5-year total return — side by side.
PRGO
Perrigo Company plc
Drug Manufacturers - Specialty & Generic
Market Cap$1.61B
5Y Perf.-78.6%
EBS vs PRGO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | EBS | PRGO |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $472M | $1.61B |
| Revenue (TTM) | $743M | $4.18B |
| Net Income (TTM) | $53M | $-1.82B |
| Gross Margin | 47.1% | 34.2% |
| Operating Margin | 14.7% | -4.1% |
| Forward P/E | 17.6x | 5.6x |
| Total Debt | $572M | $3.97B |
| Cash & Equiv. | $205M | $532M |
EBS vs PRGO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
EBS
PRGO
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Emergent BioSolutio… (EBS) | 100 | 10.9 | -89.1% |
| Perrigo Company plc (PRGO) | 100 | 21.4 | -78.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EBS vs PRGO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PRGO leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Emergent BioSolutions Inc. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
EBS
Emergent BioSolutions Inc.
The Long-Run Compounder
EBS is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- -76.6% 10Y total return vs PRGO's -77.7%
- Lower volatility, beta 1.83, current ratio 5.01x
- 7.1% margin vs PRGO's -43.5%
Best for: long-term compounding and sleep-well-at-night
PRGO
Perrigo Company plc
The Income Pick
PRGO carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 10 yrs, beta 1.18, yield 9.8%
- Rev growth -2.8%, EPS growth -7.2%, 3Y rev CAGR -1.5%
- Beta 1.18, yield 9.8%, current ratio 2.76x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PRGO | -2.8% revenue growth vs EBS's -28.8% |
| Value | PRGO | Lower P/E (5.6x vs 17.6x) |
| Quality / Margins | EBS | 7.1% margin vs PRGO's -43.5% |
| Stability / Safety | PRGO | Beta 1.18 vs EBS's 1.83 |
| Dividends | PRGO | 9.8% yield; 10-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | EBS | +92.7% vs PRGO's -51.2% |
| Efficiency (ROA) | EBS | 3.7% ROA vs PRGO's -19.8%, ROIC 8.5% vs 3.7% |
EBS vs PRGO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
EBS vs PRGO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLEBSLAGGINGPRGO
PRGOPerrigo Company plc
2leads
EBSEmergent BioSolutions…
3leads
6 Total Categories
CATEGORYLEADERvs PRGOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
EBS5/6
Valuation MetricsMultiples, price ratios, and targets
PRGO4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
EBS9/9
Total Returns1Y, 3Y, 5Y total returns with dividends
EBS4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
PRGO1/1
Income & Cash Flow (Last 12 Months)
EBS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PRGO is the larger business by revenue, generating $4.2B annually — 5.6x EBS's $743M. EBS is the more profitable business, keeping 7.1% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, PRGO holds the edge at -7.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | EBSEmergent BioSolut… | PRGOPerrigo Company p… |
|---|---|---|
| RevenueTrailing 12 months | $743M | $4.2B |
| EBITDAEarnings before interest/tax | $207M | $58M |
| Net IncomeAfter-tax profit | $53M | -$1.8B |
| Free Cash FlowCash after capex | $157M | $108M |
| Gross MarginGross profit ÷ Revenue | +47.1% | +34.2% |
| Operating MarginEBIT ÷ Revenue | +14.7% | -4.1% |
| Net MarginNet income ÷ Revenue | +7.1% | -43.5% |
| FCF MarginFCF ÷ Revenue | +21.1% | +2.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -23.6% | -7.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -76.3% | -56.4% |
EBS leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
PRGO leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, EBS's 4.0x EV/EBITDA is more attractive than PRGO's 7.4x.
| Metric | EBSEmergent BioSolut… | PRGOPerrigo Company p… |
|---|---|---|
| Market CapShares × price | $472M | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $838M | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | 9.82x | -1.14x |
| Forward P/EPrice ÷ next-FY EPS est. | 17.57x | 5.56x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 4.02x | 7.42x |
| Price / SalesMarket cap ÷ Revenue | 0.64x | 0.38x |
| Price / BookPrice ÷ Book value/share | 0.99x | 0.55x |
| Price / FCFMarket cap ÷ FCF | 3.01x | 11.12x |
PRGO leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
EBS leads this category, winning 9 of 9 comparable metrics.
Profitability & Efficiency
EBS delivers a 9.6% return on equity — every $100 of shareholder capital generates $10 in annual profit, vs $-51 for PRGO. EBS carries lower financial leverage with a 1.09x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), EBS scores 7/9 vs PRGO's 4/9, reflecting strong financial health.
| Metric | EBSEmergent BioSolut… | PRGOPerrigo Company p… |
|---|---|---|
| ROE (TTM)Return on equity | +9.6% | -50.7% |
| ROA (TTM)Return on assets | +3.7% | -19.8% |
| ROICReturn on invested capital | +8.5% | +3.7% |
| ROCEReturn on capital employed | +9.1% | +4.3% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 4 |
| Debt / EquityFinancial leverage | 1.09x | 1.35x |
| Net DebtTotal debt minus cash | $367M | $3.4B |
| Cash & Equiv.Liquid assets | $205M | $532M |
| Total DebtShort + long-term debt | $572M | $4.0B |
| Interest CoverageEBIT ÷ Interest expense | 1.84x | -7.20x |
EBS leads this category, winning 9 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
EBS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRGO five years ago would be worth $3,986 today (with dividends reinvested), compared to $1,482 for EBS. Over the past 12 months, EBS leads with a +92.7% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors EBS at 0.1% vs PRGO's -25.2% — a key indicator of consistent wealth creation.
| Metric | EBSEmergent BioSolut… | PRGOPerrigo Company p… |
|---|---|---|
| YTD ReturnYear-to-date | -27.0% | -13.5% |
| 1-Year ReturnPast 12 months | +92.7% | -51.2% |
| 3-Year ReturnCumulative with dividends | +0.2% | -58.1% |
| 5-Year ReturnCumulative with dividends | -85.2% | -60.1% |
| 10-Year ReturnCumulative with dividends | -76.6% | -77.7% |
| CAGR (3Y)Annualised 3-year return | +0.1% | -25.2% |
EBS leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — EBS and PRGO each lead in 1 of 2 comparable metrics.
Risk & Volatility
PRGO is the less volatile stock with a 1.18 beta — it tends to amplify market swings less than EBS's 1.83 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EBS currently trades 65.0% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | EBSEmergent BioSolut… | PRGOPerrigo Company p… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.83x | 1.18x |
| 52-Week HighHighest price in past year | $14.06 | $28.44 |
| 52-Week LowLowest price in past year | $4.72 | $9.23 |
| % of 52W HighCurrent price vs 52-week peak | +65.0% | +41.2% |
| RSI (14)Momentum oscillator 0–100 | 61.4 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 873K | 3.4M |
Evenly matched — EBS and PRGO each lead in 1 of 2 comparable metrics.
Analyst Outlook
PRGO leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates EBS as "Buy" and PRGO as "Hold". Consensus price targets imply 70.6% upside for PRGO (target: $20) vs 31.4% for EBS (target: $12). PRGO is the only dividend payer here at 9.81% yield — a key consideration for income-focused portfolios.
| Metric | EBSEmergent BioSolut… | PRGOPerrigo Company p… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $12.00 | $20.00 |
| # AnalystsCovering analysts | 15 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | +9.8% |
| Dividend StreakConsecutive years of raises | 1 | 10 |
| Dividend / ShareAnnual DPS | — | $1.15 |
| Buyback YieldShare repurchases ÷ mkt cap | +5.3% | 0.0% |
PRGO leads this category, winning 1 of 1 comparable metric.
Key Takeaway
EBS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
Best OverallEmergent BioSolutions Inc. (EBS)Leads 3 of 6 categories
Loading custom metrics...
EBS vs PRGO: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is EBS or PRGO a better buy right now?
For growth investors, Perrigo Company plc (PRGO) is the stronger pick with -2.
8% revenue growth year-over-year, versus -28. 8% for Emergent BioSolutions Inc. (EBS). Emergent BioSolutions Inc. (EBS) offers the better valuation at 9. 8x trailing P/E (17. 6x forward), making it the more compelling value choice. Analysts rate Emergent BioSolutions Inc. (EBS) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — EBS or PRGO?
On forward P/E, Perrigo Company plc is actually cheaper at 5.
6x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — EBS or PRGO?
Over the past 5 years, Perrigo Company plc (PRGO) delivered a total return of -60.
1%, compared to -85. 2% for Emergent BioSolutions Inc. (EBS). Over 10 years, the gap is even starker: EBS returned -76. 6% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — EBS or PRGO?
By beta (market sensitivity over 5 years), Perrigo Company plc (PRGO) is the lower-risk stock at 1.
18β versus Emergent BioSolutions Inc. 's 1. 83β — meaning EBS is approximately 55% more volatile than PRGO relative to the S&P 500. On balance sheet safety, Emergent BioSolutions Inc. (EBS) carries a lower debt/equity ratio of 109% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.
05Which is growing faster — EBS or PRGO?
By revenue growth (latest reported year), Perrigo Company plc (PRGO) is pulling ahead at -2.
8% versus -28. 8% for Emergent BioSolutions Inc. (EBS). On earnings-per-share growth, the picture is similar: Emergent BioSolutions Inc. grew EPS 125. 8% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, PRGO leads at -1. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — EBS or PRGO?
Emergent BioSolutions Inc.
(EBS) is the more profitable company, earning 7. 1% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 7. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EBS leads at 14. 8% versus 8. 1% for PRGO. At the gross margin level — before operating expenses — EBS leads at 47. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is EBS or PRGO more undervalued right now?
On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.
6x forward P/E versus 17. 6x for Emergent BioSolutions Inc. — 12. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.
08Which pays a better dividend — EBS or PRGO?
In this comparison, PRGO (9.
8% yield) pays a dividend. EBS does not pay a meaningful dividend and should not be held primarily for income.
09Is EBS or PRGO better for a retirement portfolio?
For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
18), 9. 8% yield). Emergent BioSolutions Inc. (EBS) carries a higher beta of 1. 83 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRGO: -77. 7%, EBS: -76. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between EBS and PRGO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: EBS is a small-cap deep-value stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while EBS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(EBS: -23.6% · PRGO: -7.2%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.